a public good project by the
Synthesis
Company
of California

© 2026

John Bridgewater | doi.page

0 works0 citations0 h-index

John Bridgewater

University College Hospital(GB)University College London Hospitals NHS Foundation Trust(GB)Cancer Research UK(GB)London Cancer(GB)CRUK Lung Cancer Centre of Excellence(GB)University College London(GB)

Publications by Year

Research Areas

Cholangiocarcinoma and Gallbladder Cancer Studies, Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Gastric Cancer Management and Outcomes, Gallbladder and Bile Duct Disorders

Most-Cited Works

→ Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer(2010)4,329 cited
→ Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer(2004)3,623 cited
→ Cholangiocarcinoma 2020: the next horizon in mechanisms and management(2020)2,374 cited
→ Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial(2009)2,274 cited
→ Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma(2014)1,526 cited
→ Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study(2019)1,194 cited

→ Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study(2020)

1,025 cited

→ Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial(2011)965 cited

→ Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial(2021)725 cited

→ Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial(2013)601 cited